Wayne Kuznar

Skip to main content

Home
Issues
Special Issues
Topics
Conference Correspondent
- ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
About

Home
Issues
Special Issues
Topics
Conference Correspondent
- ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
About

Authored Items

ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Disparities in Cancer Care, Conference Highlights ASCO

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma, Conference Highlights ASCO

Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Melanoma, Conference Highlights ASCO

Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Conference Highlights ASCO

Zanidatamab Shows Promising Activity in Patients with HER2-Overexpressing Gastric Cancers

Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Leukemia

Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Leukemia

Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High- Risk Myelodysplastic Syndromes

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology

ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Value-Based Care

Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma

Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma

Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology

Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology

Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Ovarian Cancer

ASCO 2020 Presidential Address: Accelerating Progress, Prioritizing Diversity

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Value-Based Care

Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Lung Cancer

Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Lung Cancer

Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma

August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Leukemia, Lymphoma

Preparing for Healthcare After COVID-19: New Challenges Facing Payers

June 2020 Vol 13, No 3 in Industry Trends

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Leukemia

Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Leukemia

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Leukemia

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Conference Highlights ASH

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology in Lymphoma

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology

Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Lung Cancer

Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Biomarkers

Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Cholangiocarcinoma

Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Emerging Therapies

Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Emerging Therapies

ASCO 2019 Presidential Address: Removing Disparities in Cancer Care

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Disparities in Oncology

The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Pediatric Cancer

BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion

August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights in Lung Cancer

Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights

Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights

Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Leukemia

AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Emerging Therapies

Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Lymphoma

Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights in Emerging Therapies

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

August 2018 Vol 11, Special Issue

Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer See also Value-Based Care

August 2018 Vol 11, Special Issue in Lung Cancer

Precision Medicine and Immunotherapy Highlighted at ASCO 2018

August 2018 Vol 11, Special Issue in Conference Highlights ASCO

Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer

August 2018 Vol 11, Special Issue

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

August 2018 Vol 11, Special Issue in Immunotherapy

IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer

August 2018 Vol 11, Special Issue

NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer

August 2018 Vol 11, Special Issue in Lung Cancer

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

August 2018 Vol 11, Special Issue in Multiple Myeloma

Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Lung Cancer

Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Breast Cancer

CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Multiple Myeloma

ASCO President Lists Progress Made in Cancer, Highlighting Current Priorities

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights

Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Prostate Cancer

In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Leukemia

Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Emerging Therapies

Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Emerging Therapies

Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights in Lymphoma

Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Leukemia

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Multiple Myeloma

Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Lymphoma

Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Lymphoma

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Emerging Therapies

Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Multiple Myeloma

The Hematology Pipeline Features New Immune Therapies, and Targeted Agents

February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights in Emerging Therapies

Cost, Access, and Delivery Challenge New Oncology Drug Options

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Value-Based Oncology Management and Outcomes-Based Contracting

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Cost-Savings Measures Will Dot the Oncology Landscape

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

ASCO CEO Addresses Quest for Value in Cancer Care

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Quality Measures Are Key to Supporting Drug Value

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Cancer Treatment Costs and Trends Beckon Risk-Sharing Future

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

PhRMA’s Perspective on Value-Driven Healthcare

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

AVBCC Sixth Annual Conference: The Evolution of Value-Based Cancer Care

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Conference Correspondent

Practice Transformation Essential to the Oncology Care Model

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Specialty Pharmacies Add Value in the Management of Cancer Drugs

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights

Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Immunotherapy

Employers Look to Manage the Benefits of Specialty Pharmacy

December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights in Employers’ Perspective

CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Leukemia

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma

Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology

Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Multiple Myeloma

Nivolumab plus Ipilimumab Combination Promotes Durable Responses in Advanced Lung Cancer

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Lung Cancer

Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Lung Cancer

Novel Vaccine Induces Immunologic Responses in Patients with Acute Myeloid Leukemia

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Novel Chimeric Monoclonal Antibody Improves Survival in Advanced Gastric Cancers

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Adding the BCL-2 Inhibitor Venetoclax to Treatment Regimen Promising in Relapsed or Refractory Multiple Myeloma

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

ASCO President Addresses Quality Care Through Collective Wisdom

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology

The Oncology Drug Pipeline Shows No Evidence of Slowing Down

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Oncology Pipeline Full, and Not Just with Immunotherapies

Caroline Helwick, Wayne Kuznar

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Care Pathway for NSCLC Cuts Chemotherapy Cost

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Nivolumab Makes Headwinds into Liver Cancer

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

ASP plus 6% Will Fall by the Wayside, but What Are the Alternatives?

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Monthly Care Management Payments Called “Win-Win-Win” Reform

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Enhanced Reimbursement for Oncology Services Pays for Patient-Centered Care

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

The Push Toward Value-Based Payment for Oncology

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers

August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

CAR-T Achieves High Rate of Remission in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Leukemia

Pracinostat-Azacitidine Combination Generates Responses in Older Adults with Acute Myeloid Leukemia

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Leukemia

Immunotherapy with PD-1 Inhibitors the Newest Breakthrough in Hodgkin Lymphoma

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Lymphoma

Orphan Drug Expenditures in the United States Expected to Stabilize

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

The Hematology Pipeline Is Abundant

Wayne Kuznar, Kate Smith

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in Emerging Therapies

Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Breast Cancer

Necitumumab Extends Survival of Patients with Squamous Lung Cancer

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Lung Cancer

Federal Spending on Cancer Research and Access to Care Woefully Inadequate

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

Upfront Docetaxel Markedly Improves Survival in Metastatic Prostate Cancer, at Reduced Cost

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Prostate Cancer

Should Oncologists Consider Interests of Society at Large When Treating the Individual Patient?

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

Even When Adjusting for Improved Survival, Newer Cancer Drugs More Expensive Than Older Ones

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

Patients with Cancer Are Not Asking for Costly, Excessive Treatments

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

2014 Oncology Pipeline Looks Impressive

Caroline Helwick, Wayne Kuznar

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Emerging Therapies

Payment Reform Key to Value-Based Cancer Care

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia

Hospital Readmission After Stem-Cell Transplant Decreases Survival

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Conference Highlights ASH

JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Conference Highlights ASH

Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Lymphoma

Promise of Genomic Sequencing for Clinical Decision-Making in Hematopoietic Cancers

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Nilotinib Sustains Deeper Molecular Response versus Imatinib in Patients with Ph+ CML

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia

Novel Anti-CD20 Antibodies Show Promising Results in Unfit Patients with Chronic Lymphocytic Leukemia

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia

Rituximab Infusions Costlier When Given in the Hospital

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Physicians Must Consider the Financial Burden of Allogeneic Transplants

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Promising Drugs in the Pipeline for Leukemia and Myelodysplastic Syndromes

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Leukemia

Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%

August 2013, Vol 6 ADA 2013 Highlights

Financial Incentives Can Promote Maintenance of Weight Loss, a Major Factor in Diabetes

August 2013, Vol 6 ADA 2013 Highlights

Future of Healthcare Reform: Expect New Payment and Delivery Models

August 2013, Vol 6 ADA 2013 Highlights

GLP-1 Agonists May Protect Patients with Diabetes from Heart Failure

August 2013, Vol 6 ADA 2013 Highlights in Emerging Therapies

Look AHEAD: Lifestyle Intervention Cost-Effective in Overweight Patients with Type 2 Diabetes

August 2013, Vol 6 ADA 2013 Highlights

SGLT-2 Inhibitors Show Durability in Glycemic Control, Weight-Loss Maintenance

August 2013, Vol 6 ADA 2013 Highlights in Emerging Therapies

Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer

August 2013 Vol 6, No 6 Special Issue

New Analysis Confirms Radium Ra-223 Prolongs Survival in Patients with Metastatic CRPC, Regardless of Previous Docetaxel Therapy Status

August 2013 Vol 6, No 6 Special Issue in Prostate Cancer

Lack of Knowledge Prevents Men with Early-Stage Prostate Cancer from Choosing Active Surveillance

August 2013 Vol 6, No 6 Special Issue in Prostate Cancer

New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer

August 2013 Vol 6, No 6 Special Issue in Breast Cancer

Current Treatment of Advanced NSCLC Requires Testing for Driver Mutations

August 2013 Vol 6, No 6 Special Issue in Lung Cancer

Afatinib Doubles Progression-Free Survival Compared with Chemotherapy in Patients with Lung Cancer

August 2013 Vol 6, No 6 Special Issue in Lung Cancer

Dabrafenib Shows Promising Results in Patients with Stage IV NSCLC

August 2013 Vol 6, No 6 Special Issue in Lung Cancer

Mammography Screening Rates Enhanced by Copay Elimination

August 2013 Vol 6, No 6 Special Issue

Causes of Hospital Readmissions of Patients with Cancer

August 2013 Vol 6, No 6 Special Issue

Poor Adherence to Oral Cancer Drugs a Growing Concern

August 2013 Vol 6, No 6 Special Issue

Use of High-Cost Diagnostic Tests for Lung Cancer Surveillance Rising

August 2013 Vol 6, No 6 Special Issue

Essential Health Benefits, Comparative Effectiveness Research, Payment Models All Play a Role in the ACA

August 2013 Vol 6, No 6 Special Issue

Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient

August 2013 Vol 6, No 6 Special Issue

ASCO President Highlights Bridges to Conquer Cancer

August 2013 Vol 6, No 6 Special Issue

Cancer Drug Pipeline Is Bustling

Caroline Helwick, Wayne Kuznar

August 2013 Vol 6, No 6 Special Issue

Weight Loss Intervention Fails to Reduce Cardiovascular Events in Type 2 Diabetes, but Has Positive Effect on Other Measures

Low-Cost Phone Intervention Helps with Weight Loss, Glycemic Control

Symptomatic hypoglycemia increases risk of cardiovascular events, death in type 2 diabetes

Achieving glucose, blood pressure, and lipid targets improving among diabetic patients, but there’s still long way to go

Cardiovascular data confirm metformin over sulfonylurea as initial treatment choice in type 2 diabetes

Web Exclusives in Cardiometabolic Health

Does insulin increase the risk of type 2 diabetes-related complications?

PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes

February 2013 Vol 6, No 1, Special Issue in Lymphoma

NIH Research Funding Cuts Would Have Devastating Impact on Hematology

February 2013 Vol 6, No 1, Special Issue

Alternatives to “7 + 3” Induction Therapy for AML Are Emerging

February 2013 Vol 6, No 1, Special Issue in Leukemia

Fast Response Identifies Patients with CML for Entry into Studies of Imatinib Discontinuation

February 2013 Vol 6, No 1, Special Issue in Leukemia

New Oral TKI Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia

February 2013 Vol 6, No 1, Special Issue in Leukemia

Combined Chemoradiation Cost-Effective in Younger Patients with Primary CNS Lymphoma

February 2013 Vol 6, No 1, Special Issue

Selective JAK Inhibitor Cost-Effective Option for Patients with Myelofibrosis

February 2013 Vol 6, No 1, Special Issue

New Targeted Agent Shows Significant Success in Treating Refractory Form of AML

February 2013 Vol 6, No 1, Special Issue in Leukemia

Measuring Coronary Calcium in Patients with Type 2 Diabetes Improves CVD Risk Assessment

CABG Surgery Outcomes Superior to PCI and Cost-Effective in Patients with Diabetes and Multivessel CAD

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3

Probiotic Reduces LDL Cholesterol Level

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3

Not All Omega-3 Fatty Acids Have the Same Effects on Lipids

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3

Alternative Anticoagulants to Warfarin Reduce Vascular Risk in Patients with NVAF

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health

Lipid Therapy Update: HDL Therapies Falling Short, Promising LDL Agents, 2 Potential Treatments for Familial Hypercholesterolemia

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3

New Hypertension Guidelines Will Be Strictly Evidence-Based

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3

Behavioral Interventions Can Result in Weight Loss

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3

Interventions for Cardiovascular Risk Reduction in Type 2 Diabetes Must Be Multifactorial

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health

Several Antihypertensive Drug Combinations Increase the Risk for Incident Diabetes

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health

Control of 4 Risk Factors Would Slash CHD Rate in Diabetes by Half

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Cardiometabolic Health

GLP-1 Agonism Holds Promise for Preventing Macrovascular Disease in Type 2 Diabetes

Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3 in Emerging Therapies

Weight loss from lifestyle changes does not reduce adverse cardiovascular outcomes in patients with type 2 diabetes

New ADA-EASD Position Statement on Managing Hyperglycemia in Type 2 Diabetes favors Individualized Approach

Mounting Evidence that DPP-4 Inhibitors may Reduce Cardiovascular Risk

Incretin Therapies Lower Cardiovascular Risk Score

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Cardiometabolic Health

The Diabetes Epidemic Is Like a Tsunami Hitting in Waves

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

Diabetes Rates Surging Among American Youth

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Cardiometabolic Health

Primary Care Physicians Underdiagnose Chronic Kidney Disease in Diabetic Patients

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

Paying Patients to Change Their Health Behavior Is Effective

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

Value-Based Benefit Design: Reducing Copayment for High-Value Services Maximizes Return on Investment

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

DPP-4 Inhibitors Improve Glycemic Control in Elderly Patients with Diabetes

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

1 in 4 Patients with Type 2 Diabetes Does Not Take Basal Insulin as Prescribed

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

Quality Improvement Programs Enhance Diabetes Care, Especially When Baseline Measures Are Poor

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

Early Intensive Therapy in Type 2 Diabetes Preserves Beta-Cell Function

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

New Long-Acting Insulin Degludec Lowers Hypoglycemia Significantly versus Insulin Glargine

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Emerging Therapies

The Ancient Anti-Inflammatory Drug Salsalate Lowers Blood Glucose Levels

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Emerging Therapies

Diabetes Drug Pipeline: Promising Agents in Late Stages of Development

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Emerging Therapies

Head-to-Head Comparison: Early Insulin Glargine Can Help Achieve Glycemic Target in Type 2 Diabetes

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights

Glycemic Control in Patients with Type 2 Diabetes Significantly Lowers Cardiovascular Disease Risk

August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights in Cardiometabolic Health

Early Intensive Therapy in Type 2 Diabetes Preserves Beta-Cell Function

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Quality Improvement Programs Enhance Diabetes Care, Especially When Baseline Measures Are Poor

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

1 in 4 Patients with Type 2 Diabetes Does Not Take Basal Insulin as Prescribed

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Diabetes Drug Pipeline: Promising Agents in Late Stages of Development

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies

The Ancient Anti-Inflammatory Drug Salsalate Lowers Blood Glucose Levels

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies

Head-to-Head Comparison: Early Insulin Glargine Can Help Achieve Glycemic Target in Type 2 Diabetes

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

The Diabetes Epidemic Is Like a Tsunami Hitting in Waves

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Novel Basal Insulin LY2605541 Lowers Blood Glucose, Enhances Weight Loss

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies

New Long-Acting Insulin Degludec Lowers Hypoglycemia Significantly versus Insulin Glargine

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Emerging Therapies

Value-Based Benefit Design: Reducing Copayment for High-Value Services Maximizes Return on Investment

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Diabetes Rates Surging Among American Youth

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Cardiometabolic Health

Paying Patients to Change Their Health Behavior Is Effective

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Primary Care Physicians Underdiagnose Chronic Kidney Disease in Diabetic Patients

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Glycemic Control in Patients with Type 2 Diabetes Significantly Lowers Cardiovascular Disease Risk

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Cardiometabolic Health

DPP-4 Inhibitors Improve Glycemic Control in Elderly Patients with Diabetes

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2

Incretin Therapies Lower Cardiovascular Risk Score

Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2 in Cardiometabolic Health

In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer

A Promising New Gene Test to Differentiate Between Aggressive and Indolent Disease

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer

Agent that Targets Heat Shock Protein Shows Activity in Castration-Resistant Prostate Cancer

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer

Abiraterone Before Chemotherapy a Successful Strategy in Prostate Cancer

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer

The Oncology Drug Pipeline Robust with Novel Agents

Caroline Helwick, Wayne Kuznar

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Pipeline

Family History of Cancer/Genetic Counseling Often Lacking for Patients First Presenting with Malignancy

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective

Cancer Therapies in Short Supply Prompt a Response at the Federal Level

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective

Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Renal-Cell Carcinoma

Non–Small-Cell Lung Cancer Testing Can Be Offered Routinely in Community Hospitals

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Lung Cancer

Quality of Life Drives Patient Preference for Metastatic RCC Drug

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Renal-Cell Carcinoma

Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Lung Cancer

Enzalutamide Extends Survival, Improves QOL in Advanced Prostate Cancer

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Prostate Cancer

Levels of Gene Expression a New Noninvasive Way to Identify Obstructive CAD

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Cardiometabolic Health

Triple-Antiplatelet Therapy Equal to Double-Dose Dual Therapy After Percutaneous Coronary Intervention

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Cardiometabolic Health

Single-Agent Oral Regimen as Effective as Current Standard for Pulmonary Embolism, Less Bleeding

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1 in Cardiometabolic Health

Monoclonal Antibody Produces Powerful Reductions in LDL Cholesterol

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

Low-Potency Statins Initiated in High-Risk Patients in a Managed Care Setting

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

New Drug Therapies for Difficult-to-Control Atrial Fibrillation

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

Blood Assay for Galectin-3 Identifies Heart Failure Risk of Patients in the Community Setting

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

IMMEDIATE: Early Use of Inexpensive Glucose-Insulin- Potassium Solution Can Prevent Cardiac Arrest in ACS

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

Value of New Anticoagulants in Acute Coronary Syndrome Still Unclear

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

Consider Combination Therapy for Patients with Low- and High-Risk Hypertension

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

Lipid-Lowering Drug Pipeline: There Is Life After Statins

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

New Oral Anticoagulants Show Superior Efficacy versus Warfarin, and No Need for Monitoring

Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1

Anti-VEGF Antibody Injections Improve Vision in Diabetic Macular Edema

Web Exclusives in Conference Highlights ADA

Artificial Pancreas Passes Test in Patients with Type 1 Diabetes

Web Exclusives in Conference Highlights ADA

Medical Food Improves Symptoms of Diabetic Neuropathy

Web Exclusives in Conference Highlights ADA

Education, Counseling Associated with Improved Clinical Outcomes in Type 2 Diabetes

Web Exclusives in Conference Highlights ADA

Treatment Satisfaction Highest for Diabetic Patients Taking Only Oral Medications

Web Exclusives in Conference Highlights ADA

Adding Saxagliptin to Metformin Improves Glycemic Control Over Uptitrating Metformin Dose

Web Exclusives in Conference Highlights ADA

Diabetes Prevention with Metformin Is Cost-Saving for Persons at High Risk

Web Exclusives in Conference Highlights ADA

Blood Glucose Testing a Significant Contributor to Pharmacy Costs in Patients Using Insulin

Web Exclusives in Conference Highlights ADA

Insulin Inappropriately Discontinued in Many Type 2 Diabetes Patients After Hospitalization

Web Exclusives in Conference Highlights ADA

Cutting-Edge Data Presented at ADA 2011 Highlight the Diabetes–Cardiovascular Disease Link

September/October 2011 Volume 4, Number 6 in Conference Highlights ADA

Economic Recession Affects Rates of Cancer Incidence and Treatment

August 2011 Vol 4, No 4, Special Issue

Multiple Myeloma Treatments Are Moving Rapidly from Bench to Bedside

August 2011 Vol 4, No 4, Special Issue in Multiple Myeloma

Cabozantinib Shows Dramatic Effects on Bone Metastases in Advanced Prostate Cancer

August 2011 Vol 4, No 4, Special Issue in Prostate Cancer

Get Ready for the New Era of “Genomic Chaos” in Cancer Care

August 2011 Vol 4, No 4, Special Issue

Medicaid Reimbursement for Cancer Screening Lags Inflation

August 2011 Vol 4, No 4, Special Issue

Patients Want to Discuss Cost of Care, Oncologists Often Avoid It

August 2011 Vol 4, No 4, Special Issue

Novel Selective Beta-Agonist Improves Lung Function in COPD: Preliminary Analysis

First Acute COPD Exacerbation a Significant Risk for Death within 4 Years

Heading Off Exacerbations in COPD Is Crucial

Worsening Symptoms, Lung Function Precede COPD Exacerbations

Systemic Effects of COPD Linked to Many Comorbidities, Affect Treatment Decisions, Increase Costs

Roflumilast Improves Lung Function Independent of Inhaled Corticosteroids

Novel PDE 4 Inhibitor Cuts COPD Exacerbations

Dry Powder Inhalers Compared for Correct Use, Ease of Handling: Breezhaler versus HandiHaler

New Developments in Aerosol Delivery Aim to Improve Therapeutic Efficacy

Performance, Preference Vary for COPD Inhalers

Selecting an Inhalation Device for COPD Should Consider Peak Flow Rates, Patient Satisfaction

Expect Widespread Adoption of P4P as Healthcare Spending Increases

COPD Alliance Aims for Better Recognition and Care of COPD

COPD Treatment Complexity Affects Adherence, Resource Utilization

Burden of COPD on Older Employees Is Substantial

Total Annual COPD Costs Top $4000 per Patient

Emerging Drugs for COPD Target Lung Function, Inflammation, Smooth-Muscle Cells in Airways

Investigational Anticholinergic Achieves Early Bronchodilation

Patients with COPD and Their Caregivers Are Satisfied with Nebulizer Therapy

Chest 2010 Explores State-ofthe- Art Management of COPD and Treatments on the Horizon

Healthcare Reform Must Include Multiple Components

Bustling Pipeline for Diabetes and Its Metabolic Consequences

July/August 2008, Vol 1, No 6

Healthcare Reform Must Include Multiple Components

Web Exclusives in Health Policy and Reform

Wayne Kuznar, Nirav R. Shah, MD,MPH, F. Randy Vogenberg, PhD, FASHP

February/March 2009, Vol 2, No 2 in FDA Approvals, Perspectives

Bustling Pipeline for Diabetes and Its Metabolic Consequences

July/August 2008, Vol 1, No 6

The Antiplatelet Drug Pipeline: Some Promising Candidates

November/December 2008, Vol 1, No 9 in Conference Highlights AHA

An Overview of Cholesterol Management

Robyn A. Burns Schaiff, PharmD, BCPS, Wayne Kuznar, Richard M. Moe, MD, PhD, Daniel W. Krichbaum, PharmD

November/December 2008, Vol 1, No 9 in Clinical

The Cardiovascular Pipeline: ACC 2010 Features Late-Stage Drugs

March/April 2010, Vol 3, No 2 in Pipeline

Cardiology Pipeline Is Promising: AHA 2009

January/February 2010, Vol 3, No 1 in Industry Trends

The Cardiology Pipeline

Web Exclusives in Pipeline

Diabetes Pipeline: New Strategies Emerging for Glycemic Control

Web Exclusives in Pipeline

Last modified: September 6, 2013

SUBSCRIBE

HOME
ABOUT
CONTACT US
TERMS OF USE
PRIVACY POLICY
ADVERTISING POLICY

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Special Print Editions

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.